Retatrutide is a triple hormone receptor agonist being developed primarily for the treatment of obesity and type 2 diabetes by Eli Lilly. 🔬 How it works Retatrutide activates three key metabolic hormone receptors: GLP-1 (glucagon-like peptide-1) receptor – enhances insulin secretion, reduces appetite, and slows gastric emptying. GIP (glucose-dependent insulinotropic polypeptide) receptor – supports insulin release and may have direct effects on fat metabolism. Glucagon receptor – increases energy expenditure and fat burning (in controlled activation). This triple action aims to produce stronger weight loss and metabolic improvements than current GLP-1/GIP drugs such as semaglutide (Wegovy/Ozempic) or tirzepatide (Mounjaro/Zepbound), which are dual agonists (GLP-1 + GIP)